BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) E-Tattoo Will Be ‘Next Wave of Innovation for Neurology’

February 22, 2021 15:07:51

Brain Scientific (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. As scientists work to understand what causes Parkinson’s, Alzheimer’s, dementia and other neurological issues, BRSF is making inroads in helping identify root neurological problems. The company has unveiled a new initiative to develop an innovative e-tattoo device for the brain diagnostics market. The Brain E-Tattoo’s graphene-based electrodes are designed for connection to the micro EEG clipped behind the ear, which processes the signals from the sensors and wirelessly transfers data to a cloud application. The solution enables each patient’s data to be secured in the cloud where Brain Scientific’s artificial intelligence performs continuous analysis, providing 24/7 uninterrupted seizure monitoring. Dating back to 1929, drastic advances to the EEG have only been seen in the last few decades. “COVID-19 put a spotlight on the outdated and inefficient EEG testing protocols,” said Boris Goldstein, BRSF co-founder and executive. “Disposable technology made a significant impact to ensure brain scans could occur safely during the pandemic. Now, brain e-tattoos implanted in the forehead will be the next wave of innovation for neurology. The advancement will allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions. Clinicians will be able to identify brain wave activity beyond the clinical setting with no impact to the patient’s daily life. While we aren’t yet ready as a society to cyborg our way past neurological issues, we are on the cusp of better understanding and diagnosing them. Thanks to cutting-edge technology like BRSF’s E-Tattoo, answers are right around the corner.”

To view the full article, visit https://ibn.fm/O1DOu

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork